inWhite tw_white-black
MoreMenu
CloseWhite
inWhite tw_white-black

News

Asgard Therapeutics’ study published in Science showing proof-of-concept and strong anti-tumor responses via in vivo cell reprogramming with lead program AT-108

Asgard Therapeutics selects Exothera to bring their viral vector-based immunotherapy candidate AT-108 to clinical trial stage

Asgard Therapeutics announces €30 million Series A financing to advance its first-in-class in vivo cell reprogramming platform for immuno-oncology

Asgard Therapeutics to present positive in vivo efficacy data with AT-108 as monotherapy at Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting 

CEO Cristiana Pires receives 2022 RFS Award for publication in Cellular Reprogramming journal

Posted 7 August, 2023

Asgard’s Therapeutics CEO Cristiana Pires has been honored with the prestigious 2022 annual Rosalind Franklin Society (RFS), in partnership with Mary Ann Libert, Inc., publishers, Award in Science for her publication in Cellular Reprogramming journal, co-authored with Filipe Pereira, recognizing exceptional contributions of women and underrepresented minority scientists, physicians, and engineers.